Leukemia 
Welcome,         Profile    Billing    Logout  

1318 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Leukemia
2015-003940-38: Study of posaconazole blood levels comparing two different oral presentations, a syrup and a solid tablet, in patients with leukaemia at a high risk of fungal infections Estudio de niveles de posaconazol en sangre comparando dos presentaciones del fármaco, una en jarabe y otra en tabletas, en pacientes con leucemia con alto riesgo de infecciones fúngicas

Ongoing
4
20
Europe
Oral suspension, Gastro-resistant tablet, Noxafil 40 mg/ml suspensión oral, Noxafil 100 mg comprimidos gastrorresistentes
Fundación Investigación Biomédica Puerta de Hierro, Merck Sharp & Dohme España
Invasive Mycoses Micosis invasoras, Severe fungal infections Infecciones graves por hongos, Diseases [C] - Bacterial Infections and Mycoses [C01]
 
 
2016-001223-31: Incidence of Invasive Fungal Disease in Patients receiving Immunosuppressive Therapy, Intensive Chemotherapy or Reduced Intensity Haematopoietic Stem Cell Transplantation on Posaconazole tablet Prophylaxis

Ongoing
4
150
Europe
Noxafil Gastro resistant tablets, Tablet, Noxafil®
King's College Hospital NHS Foundation Trust, Merck Sharp & Dohme Limited (MSD).
Aplastic Anaemia, Myelodysplastic syndromes, Acute Myeloid Leukaemia undergoing immunosuppression therapy, high dose chemotherapy or reduced intensity stem cell transplantation, Fungal infection as a result of immunosuppressive therapy, chemotherapy or stem cell transplantation., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-000661-20: Cancer treatment with anthracyclines may cause heart damage and can lead to heart failure. There are drugs which may protect against cardiotoxic effects of anthracyclines, but they are untolerated due to hypotension. Ivabradine is heart rate lowering drug without effect on blood pressure which was approved for treatment of angina pectoris and heart failure. The aim of this study is to investigate protective effects of ivabradine in cancer patients undergoing anthracycline-based chemotherapy. Chemoterapija antraciklinais sukelia širdies raumens pažeidimą. Siekiant to išvengti yra skiriami vaistai, bet jie nepakankamai veiksmingi ir turi nepageidaujamų reiškinių. Ivabradinas yra vaistas, skirtas krūtinės angina ir lėtiniu širdies nepakankamumu sergantiems pacientams, kuris mažina pulsą nemažindamas kraujospūdžio. Tyrimo tikslas yra nustatyti, ar ivabradinas saugus ir veiksmingas vėžiu sergantiems ir antraciklinais gydomiems pacientams.

Not yet recruiting
4
150
Europe
Ivabradine Anpharm 7,5 mg, Film-coated tablet, Ivabradine Anpharm 5 mg, Ivabradine Anpharm 7,5 mg
Vilnius University Hospital Santaros klinikos, Society of cardiovascular medicine
Cancers treated with anthracyclines: leukemias, limphomas, breast, stomach, uterine, ovarian, lung. Vėžiniai susirgimai gydomi antraciklinų grupės preparatais: leukemijos, limfomos, krūties, skrandžio, gimdos, kiaušidžių, plaučių., Cancer: blood, lymphnode, breast, stomach, uterine, ovarian, lung. Vėžys: kraujo, limfmazgių, krūties, skrandžio, gimdos, kiaušidžių, plaučių., Diseases [C] - Cancer [C04]
 
 
2019-004295-18: Fibrinogen and platelets in patients with acute myeloid leukaemia and thrombocytopenia

Ongoing
4
20
Europe
Concentrate for solution for infusion, Riastap
Aarhus University Hospital, Kræftens Bekæmpelse, CSL Behring
Bleeding i patients with acute myeloid leukemia, Bleeding i patients with acute myeloid leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-002850-26: Immune response test as new predictor for successful TKI stop in patients with chronic myeloid leukemia Immuunresponstest als nieuwe voorspeller voor succesvolle TKI-stop bij patiënten met chronische myeloïde leukemie.

Not yet recruiting
4
57
Europe
Solution for injection, PNEUMOVAX 23
Albert Schweitzer Hospital, Albert Schweitzer Hospital
Chronic myeloid leukemia, Chronic myeloid leukemia is a cancer of the white blood cells and is characterized by an overgrowth of these cells in the bone marrow and the accumulation of these cells in the blood., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-000722-96: changes in lymph nodes in patients with CLL treated with venetoclax-containing regimens Modificazioni del microambiente linfonodali in pazienti con leucemia linfatica cronica CLL in trattamento con regimi contenenti venetoclax

Not yet recruiting
4
30
Europe
Venclyxto, [Venclyxto], Coated tablet, venclyxto
OSPEDALE SAN RAFFAELE, AbbVie
Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica, Chronic Lymphocytic Leukemia Leucemia Linfatica Cronica, Diseases [C] - Cancer [C04]
 
 
2019-001585-15: PTX3 genetically stratified randomized double-blinded allocation event-driven clinical trial for antifungal prophylaxis in patients with acute myeloid leukemia Etude d’allocation génétique de la prophylaxie antifongique chez les patients traités pour une leucémie aiguë myéloïde

Ongoing
4
105
Europe
Solution for infusion, Powder for solution for infusion, Capsule, Tablet, Noxafil, Diflucan
Centre Hospitalier Universitaire Vaudois, Swiss National Science Foundation
Invasive mold infections leucémie aigue myéloïde, Invasive mold infections leucémie aigue myéloïde, Not possible to specify
 
 
NCT03677596 / 2018-001557-27: A Study Of Two Inotuzumab Ozogamicin Doses in Relapsed/ Refractory Acute Lymphoblastic Leukemia Transplant Eligible Patients

Completed
4
102
Europe, US, RoW
inotuzumab ozogamicin-dose level 2, Besponsa, Inotuzumab ozogamicin-dose level 1
Pfizer
Leukemia, Precursor b-Cell Lymphoblastic Leukemia-Lymphoma, ACUTE LYMPHOBLASTIC LEUKEMIA
09/22
05/23
NCT05353205: A Study of the Efficacy and Safety of Flumatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase.

Recruiting
4
200
RoW
Flumatinib mesylate tablets (400mg), Flumatinib mesylate tablets (600mg)
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase
12/22
09/25
NCT04930536: Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell Lymphoma

Completed
4
84
RoW
Acalabrutinib capsule, Calquence®
AstraZeneca
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell Lymphoma
05/23
05/23
NCT03190330: A Study to Assess Safety of ImbruvicaTM in Indian Participants With Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy or Chronic Lymphocytic Leukemia With 17p Deletion

Completed
4
75
RoW
Ibrutinib 420 mg, Imbruvica, Ibrutinib 560 mg
Johnson & Johnson Private Limited
Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Mantle-Cell
05/23
05/23
NCT01735955 / 2012-003902-28: Study to Allow Access to Nilotinib for Patients Who Are on Nilotinib Treatment in a Novartis-sponsored Study

Completed
4
57
Europe, Canada, US, RoW
Nilotinib, AMN107
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia (CML), Metastatic Gastrointestinal Stromal Tumors (GIST), Acute Lymphoblastic Leukemia (ALL), Receptor Tyrosine Kinase (KIT) Mutated Melanoma
07/23
07/23
NCT05144243: Study to Assess Adverse Events and Change in Disease State of Oral Venetoclax in Combination With Subcutaneous (SC) Azacitidine in Newly Diagnosed Adult Participants With Acute Myeloid Leukemia (AML) Who Are Ineligible for Intensive Chemotherapy in China

Active, not recruiting
4
44
RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Genentech, Inc.
Acute Myeloid Leukemia (AML)
07/24
07/24
NCT05687032: A Study of Inotuzumab Ozogamicin in Chinese Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

Active, not recruiting
4
44
RoW
inotuzumab ozogamicin, Besponsa
Pfizer
Acute Lymphoblastic Leukemia
08/24
11/25
ASC4INDIA, NCT06427811: Clinical Study of Asciminib in Previously Treated Indian Patients With Ph+ CML-CP Without T315I Mutation and in Patients With Ph+ CML-CP With T315I Mutation

Not yet recruiting
4
85
NA
Asciminib, ABL001
Novartis Pharmaceuticals
Philadelphia Chromosome-Positive Chronic Myeloid Leukemia in Chronic Phase
04/25
04/25
NCT04506086: Feasibility Study to Evaluate Outpatient Blinatumomab in Subjects With Minimal Residual Disease (MRD) of B-precursor Acute Lymphoblastic Leukemia (ALL)

Recruiting
4
45
US
Blinatumomab, AMG 103, Blincyto, Current Wearable Heatlth Monitoring System (CWHMS)
Amgen
B-precursor Acute Lymphoblastic Leukemia
12/25
12/25
NCT05367765: A Real World Study of the Efficacy and Safety of Flumatinib Versus Imatinib in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase

Not yet recruiting
4
2400
RoW
Flumatinib, Imatinib
Jiangsu Hansoh Pharmaceutical Co., Ltd.
CML, Chronic Phase
04/27
04/28
NCT03229200 / 2016-004356-30: Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Enrolling by invitation
4
600
Europe, Canada, US, RoW
Ibrutinib
Pharmacyclics Switzerland GmbH, Janssen Biotech, Inc., including Johnson & Johnson
Lymphoma, B-Cell, Lymphoma, Non-Hodgkin, Leukemia, B-cell, Graft Vs Host Disease, Solid Tumor
05/27
05/27
NCT04877522 / 2021-000602-17: Asciminib Roll-over Study

Recruiting
4
347
Europe, Canada, Japan, US, RoW
Asciminib single agent, ABL001, Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Sprycel
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
08/30
08/30
CINC424A2X01B, NCT02386800 / 2014-003527-22: Rollover Protocol

Active, not recruiting
4
279
Europe, Canada, Japan, RoW
ruxolitinib, INC424, Jakavi, panobinostat, LBH589, Farydak
Novartis Pharmaceuticals
Primary Myelofibrosis, Polycythemia Vera, Graft Versus Host Disease, Acute Myeloid Leukemia, Thalassemia
09/27
09/27
2018-003377-97: Long term effect on immune response after pneumococcal vaccination in patients with chronic lymphocytic leukemia and evaluation of the effect of revaccination.

Ongoing
3/4
126
Europe
Pneumovax, Prevenar, Solution for injection in pre-filled syringe, Suspension for injection in pre-filled syringe, Pneumovax, Prevenar
Swedish CLL-group, Swedish CLL group
The aim of the study is to evaluate pneumococcal vaccination strategy with PPSV23 and PCV13 in patients with chronic lymphocytic leukemia (CLL) initially randomized in a clinical study., Chronich Lymphocytic Leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2020-004780-71: A study using a hormone drug during chemotherapy for fertility protection of young women and teenagers with cancer - ProFertil En studie med ett hormonpreparat som utvärderar effekten av fertilitet hos unga kvinnor och tonåringar med cancer - ProFertil

Not yet recruiting
3
500
Europe
Pamorelin, Powder and solvent for prolonged-release suspension for injection, Pamorelin
Karolinska University Hospital, Karolinska University Hospital
Breast CancerAcute LeukemiaLymphomas (Hodgkin and non-Hodgkin)Sarcomas (Osteo, Soft tissue and Ewing) Bröstcancer, Akut Leukemi, Lymfom (Hodgkin och non-Hodgkin), Sarkom (Ben, Mjukvävnad och Ewing), Breast CancerBlood CancerCancer in lymphnodesCancer in bones Bröstcancer, Blodcancer, Cancer i lymfkörtlar, Cancer i skelett, Diseases [C] - Cancer [C04]
 
 
NCT00682396: Dose-Reduced Versus Standard Conditioning Prior Allo SCT for MDS/sAML Patients

Recruiting
3
160
Europe, RoW
Standard conditioning prior allo SCT, Dose-reduced conditioning prior allo SCT
Universitätsklinikum Hamburg-Eppendorf, Pierre Fabre Medicament
Myelodysplastic Syndrome, Secondary Acute Myeloid Leukemia
05/12
05/13
2004-001719-77: A Randomized Study of Tipifarnib Versus Best Supportive Care (Including Hydroxyurea) in the Treatment of Newly Diagnosed Acute Myeloid Leukemia (AML) in Subjects 70 Years or older.

 
3
21
Europe
Zarnestra 100mg Tablets, R115777,
Johnson & Johnson Pharmaceutical Research and Development, Johnson&Johnson Pharmaceutical Research and Development, Janssen-Cilag International NV, Janssen-Cilag Limited, Johnson&Johnson Pharmaceutical Research and Development, Division de Janssen-Cilag, JANSSEN-CILAG, Janssen-Cilag International N.V.
Treatment of Acute Myeloid Leukemia (AML)
 
10/07
2008-001290-15: Study for the treatment of patients who have been succesfully treated for leukemia before, to keep the patient leukemia free

Ongoing
3
86
Europe
Vidaza, Vidaza, Vidaza
HOVON Foundation, HOVON Foundation, CELGENE, Hovon Foundation, Celgene
Acute myeloid leukemia
 
 
2009-012518-39: A phase III, open label, randomized, multicenter trial of ofatumumab maintenance treatment versus no further treatment in subjects with relapsed chronic lymphocytic leukemia (CLL) who have responded to induction therapy

Ongoing
3
60
Europe
OFATUMUMAB, GSK1841157,
GlaxoSmithKline Research and Development, GlaxoSmithKline Research and Development Limited, GlaxoSmithKline, GlaxoSmithKline Research & Development Limited, GlaxoSmithKline S.A, , GlaxoSMithKline, GlaxoSmithKline
Subjects who are in CR or PR after 1 or 2 treatments for relapsed CLL
 
 
RATIFY, NCT00651261 / 2006-006852-37: Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

Checkmark RATIFY trial for AML with FLT3 mutations at ASH 2015
Dec 2015 - Dec 2015: RATIFY trial for AML with FLT3 mutations at ASH 2015
Checkmark AML patients with FLT3 mutations
Dec 2015 - Dec 2015: AML patients with FLT3 mutations
Checkmark RATIFY trial in AML
More
Active, not recruiting
3
717
Canada, US
cytarabine, daunorubicin, midostaurin, placebo, dexamethasone acetate
Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Novartis Pharmaceuticals
Leukemia
07/16
 
2017-000764-15: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs. standard of care following allogeneic stem cell transplantation in patients with high-risk AML or MDS

Ongoing
3
350
Europe
Farydak, Capsule, hard, Farydak
Universitätsklinikum Frankfurt, Novartis Pharma GmbH
High risk acute myeloid leukemia or myelodysplastic syndrome Hoch-risiko akute myeloische Leukämie oder myelodysplastisches Syndrom, Acute myeloid leukemia (AML). Myelodysplastic syndrome (MDS) Akute myeloische Leukämie (AML). Myelodysplastisches Syndrom (MDS)., Diseases [C] - Cancer [C04]
 
 
2016-001935-12: International collaborative treatment protocol for children and adolescents with acute lymphoblastic leukemia

Ongoing
3
5420
Europe
, Powder for solution for injection, Solution for injection, Powder for concentrate for solution for infusion, Erwinase, Oncaspar, Blincyto
Universitätsklinikum Schleswig-Holstein, Campus Kiel, AIEOP- Associazione Italiana Ematologia Oncologia Pediatrica, Deutsche Krebshilfe, AMGEN
acute lymphoblastic leukemia in children and adolescents <18 yearsof age, acute lymphoblastic leukemia in children and adolescents <18 yearsof age, Diseases [C] - Cancer [C04]
 
 
CLL14 study, NCT02242942 / 2014-001810-24: Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Checkmark 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Dec 2020 - Dec 2020: 4 year data from trial in combination with obinutuzumab for previously untreated CLL at ASH 2020
Checkmark From CLL-14 trial in combination with Gazyva in CLL
Sep 2020 - Sep 2020: From CLL-14 trial in combination with Gazyva in CLL
Checkmark From CLL-14 trial in combination with Gazyva in CLL at ASCO 2020
More
Active, not recruiting
3
445
Europe, Canada, US, RoW
Chlorambucil, Venetoclax, ABT-0199, GDC-0199, Obinutuzumab, GA-101; Gazyva
Hoffmann-La Roche, AbbVie, German CLL Study Group
Lymphocytic Leukemia, Chronic
08/18
08/25
ADMIRAL, NCT02421939 / 2015-000140-42: A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation

Checkmark Readout from P3 ADMIRAL study in r/r AML
Apr 2019 - Apr 2019: Readout from P3 ADMIRAL study in r/r AML
Active, not recruiting
3
371
Europe, Canada, Japan, US, RoW
gilteritinib, ASP2215, XOSPATA®, LoDAC (Low Dose Cytarabine), Azacitidine, MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG-IDA (Granulocyte-Colony Stimulating Factor (G-CSF), Fludarabine, Cytarabine, Idarubicin)
Astellas Pharma Global Development, Inc.
Leukemia, Acute Myeloid (AML)
09/18
12/24
PHCHBS-WD4070, NCT00718263: Efficacy and Safety of Nilotinib Patients With Newly Diagnosed CML - CP (Chronic Myelogenous Leukemia - Chronic Phase)

Checkmark In 2nd line CML chronic phase pts
Feb 2014 - Feb 2014: In 2nd line CML chronic phase pts
Active, not recruiting
3
90
Japan, US, Europe, RoW
Nilotinib, Imatinib
Novartis Pharmaceuticals
Myelogenous Leukemia, Chronic
10/18
10/18
ELEVATE-TN, NCT02475681 / 2014-005582-73: Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLL

Hourglass Dec 2023 - Dec 2023 : Data from ELEVATE-TN in treatment-naive chronic lymphocytic leukemia at ASH 2023
Checkmark 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 5-year PFS data from ELEVATE CLL TN trial for CLL at ASCO 2022
Checkmark Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
Jun 2022 - Jun 2022: Presentation of data from ELEVATE TN trial in combination with obinutuzumab for 1L CLL at ASCO 2022
More
Active, not recruiting
3
535
Europe, Canada, US, RoW
Acalabrutinib, ACP-196 (Calquence), Obinutuzumab, GAZYVA / GAZYVARO, Chlorambucil, LEUKERAN
Acerta Pharma BV
Chronic Lymphocytic Leukemia
02/19
09/25
VIALE-C, NCT03069352 / 2016-003900-30: A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy

Checkmark Data from VIALE-C trial in combination with low-dose cytarabine in AML
Feb 2020 - Feb 2020: Data from VIALE-C trial in combination with low-dose cytarabine in AML
Active, not recruiting
3
211
Europe, Canada, Japan, US, RoW
Placebo, Venetoclax, ABT-199, Venclexta, Cytarabine, Cytosar-U, Ara-C, Arabinosylcytosine
AbbVie
Acute Myeloid Leukemia (AML)
02/19
07/25
IDHENTIFY, NCT02564510: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Not yet recruiting
3
280
NA
AG-221, BSC, Azacitidine, Low-dose cytarabine (LDAC), Intermediate-dose cytarabine (IDAC)
Celgene Corporation
Leukemia, Myeloid, Isocitrate Dehydrogenase
04/19
02/20
2018-002443-28: This study is being done to test the effectiveness and safety of an investigational drug called acalabrutinib (ACP-196) when taken with already marketed drugs called Venetoclax and Obinutzumab in comparison to chemotherapy that is already in wide use for treatment of patients who have chronic lymphocytic leukemia and who have never been treated before.

Not yet recruiting
3
780
Europe, RoW
acalabrutinib, ACP-196, Capsule, hard, Concentrate for solution for infusion, Powder for solution for injection/infusion, Concentrate for solution for injection/infusion, Film-coated tablet, Powder for concentrate for solution for infusion, Gazyvaro, MABTHERA, Venclyxto
Acerta Pharma B.V., ACERTA PHARMA BV, AstraZeneca, Acerta Pharma B.V., AstraZeneca AB, ASTRAZENECA AB, Acerta BV
Previously untreated Chronic Lymphocytic Leukemia Without del(17p) or TP53 Mutation, Previously untreated low-risk blood cancer, Diseases [C] - Cancer [C04]
 
 
QUAZAR AML-001, NCT01757535 / 2012-003457-28: Efficacy of Oral Azacitidine Plus Best Supportive Care as Maintenance Therapy in Subjects With Acute Myeloid Leukemia (AML) in Complete Remission

Checkmark From QUAZAR AML-001 study for post induction AML maintenance
Sep 2019 - Sep 2019: From QUAZAR AML-001 study for post induction AML maintenance
Completed
3
472
Europe, Canada, US, RoW
Oral Azacitidine, CC-486; Onureg®, Placebo
Celgene
Leukemia, Myeloid, Acute
07/19
06/24
2019-001804-39: Study to Investigate the Use of Acalabrutinib in the Treatment of Patients With Chronic Lymphocytic Leukemia Estudio para investigar el uso de acalabrutinib en el tratamiento de pacientes con Leucemia Linfocítica Crónica

Not yet recruiting
3
130
Europe
Acalabrutinib, ACP-196, Capsule, hard
Fundación PETHEMA, AstraZeneca
Early Stage CLL With High Risk of Early Disease Progression LLC en estadio temprano con alto riesgo de progresión temprana de la enfermedad, Chronic lymphocytic leukemia Leucemia Linfocítica Crónica, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2019-003327-37: A Study to Compare the Efficacy and Safety of a Combined Regimen of Venetoclax and Obinutuzumab Versus Fludarabine, Cyclophosphamide, and Rituximab (FCR)/ Bendamustine And Rituximab (BR) in FIT Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) without DEL (17P) or TP53 mutation Estudio para comparar la eficacia y seguridad de un régimen combinado de Venetoclax y Obinutuzumab versus fludarabina, ciclofosfamida y rituximab (FCR) / bendamustina y rituximab (BR) en pacientes FIT con leucemia linfocítica crónica (CLL) sin tratamiento previo sin DEL (17P) o mutación TP53

Not yet recruiting
3
165
Europe
Venclexta®, Venclyxto® or GDC-0199, Obinutuzumab, MabThera, Bendamustine, Cyclophosphamide, Fludarabine, Venclexta®, Venclyxto® or GDC- 0199, RO5537382, RO5072759, RO0452294, Film-coated tablet, Concentrate for solution for infusion, Powder for concentrate for solution for infusion, Powder for solution for injection/infusion, Venclyxto® 10 mg film-coated tablets, Gazyvaro, MabThera 500 mg concentrate for solution for infusion, Venclyxto® 50 mg film-coated tablets, Venclyxto® 100 mg film-coated tablets
F. Hoffmann-La Roche Ltd, F. HOFFMANN - LA ROCHE LTD., F. Hoffmann-La Roche Ltd
Chronic Lymphocytic Leukemia (CLL) Leucemia Linfocítica Crónica (LLC), CLL is a type of a cancer in which the bone marrow (BM) makes too many lymphocytes (a type of white blood cell) LLC es un tipo de cáncer en el cual la médula ósea (MO) produce demasiados linfocitos (un tipo de glóbulo blanco), Diseases [C] - Cancer [C04]
 
 
2019-003871-20: Study to determine the efficacy of Gemtuzumab Ozogamicin, together with standard chemotherapy, on minimal residual disease levels as well as the efficacy of Glasdegib as maintenance after transplantation, in adult patients with Acute Myeloid Leukemia (AML), a tumor characterized from an abnormal proliferation of blood cells present in the bone marrow in the form of immature myeloid "precursors", ie cells not yet differentiated, called blasts. Studio volto a determinare l'efficacia di Gemtuzumab Ozogamicin, unito alla chemioterapia standard, sui livelli di malattia minima residua oltre che l'efficacia di Glasdegib come mantenimento dopo il trapianto, in pazienti adulti affetti da Leucemia Mieloide Acuta (AML), un tumore caratterizzato da una proliferazione anomala delle cellule del sangue presenti nel midollo osseo sotto forma di «precursori» mieloidi immaturi, cioè cellule non ancora differenziate,dette blasti.

Not yet recruiting
3
414
Europe
Gemtuzumab Ozogamicin, Glasdegib, [NA], [PF-04449913], Powder for solution for infusion, Tablet, MYLOTARG 5 mg polvere per concentrato per soluzione per infusione
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Pfizer S.R.L.
Favorable-intermediate-risk Acute Myeloid Leukemia (AML) Leucemia Mieloide Acuta (LMA) a rischio favorevole o intermedio, AML disease that originates in the bone marrow (myeloid) and progresses quickly (acute). If the blood cells, maturing, undergo a transformation in the tumor sense, we have the pathology. AML malattia che origina nel midollo osseo (mieloide) e progredisce velocemente (acuta).Se le cellule del sangue, maturando, vanno incontro a una trasformazione in senso tumorale si ha la patologia., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
IDHENTIFY, NCT02577406 / 2015-000344-42: An Efficacy and Safety Study of AG-221 (CC-90007) Versus Conventional Care Regimens in Older Subjects With Late Stage Acute Myeloid Leukemia Harboring an Isocitrate Dehydrogenase 2 Mutation

Checkmark From IDHENTIFY trial in combination with best supportive care vs. conventional care regimens in r/r AML
Aug 2020 - Aug 2020: From IDHENTIFY trial in combination with best supportive care vs. conventional care regimens in r/r AML
Checkmark Study initiation in relapsed AML patients with an IDH2 mutation
Oct 2015 - Oct 2015: Study initiation in relapsed AML patients with an IDH2 mutation
Completed
3
319
Europe, Canada, US, RoW
AG-221, BSC, Azacitidine, Low-dose cytarabine (LDAC), Intermediate-dose cytarabine (IDAC)
Celgene
Leukemia, Myeloid, Isocitrate Dehydrogenase
03/20
03/24
Ascembl, NCT03106779 / 2016-002461-66: Study of Efficacy of CML-CP Patients Treated With ABL001 Versus Bosutinib, Previously Treated With 2 or More TKIs

Hourglass Jan 2019 - Dec 2019 : Completion of P3 trial
Active, not recruiting
3
233
Europe, Canada, Japan, US, RoW
Asciminib, ABL001, Bosutinib
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia
05/20
12/24
NCT03116477: Study Investigating the Efficacy of the Addition of Crenolanib to Chemotherapy vs Chemotherapy Alone in Patients With R/R FLT3 Mutated AML

Not yet recruiting
3
320
NA
Crenolanib besylate, Cytarabine, Mitoxantrone, Fludarabine, Idarubicin, G-CSF
Arog Pharmaceuticals, Inc.
Acute Myeloid Leukemia, in Relapse
08/20
08/20
ELEVATE-RR, NCT02477696 / 2014-005530-64: Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)

Checkmark Presentation of data from ELEVATE-RR trial in r/r CLL at ASH 2022
Nov 2022 - Nov 2022: Presentation of data from ELEVATE-RR trial in r/r CLL at ASH 2022
Checkmark From ELEVATE-RR trial in r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From ELEVATE-RR trial in r/r CLL at ASH 2021
Checkmark From ELEVATE-RR trial in combination with Ibrutinib for previously Treated Patients With CLL
More
Active, not recruiting
3
533
Europe, US, RoW
Acalabrutinib, ACP-196, Ibrutinib
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/20
01/28
2019-001323-12: Clinical trial comparing azacitidine plus pevonedistat versus azacitidine in patients with newly diagnosed acute myeloid leukemia who are ineligible for standard induction chemotherapy Estudo para comparar o tratamento com azacitidina mais pevonedistat em relação à azacitidina em adultos com diagnóstico de novo de LMA e que não elegíveis para a quimioterapia de indução padrão

Not yet recruiting
3
466
Europe
Pevonedistat, Concentrate for solution for infusion
Fundación PETHEMA, Millennium Pharmaceuticals, Inc
Acute Myeloid Leukemia Leucemia Mieloide Aguda, Acute Myeloid Leukemia Leucemia Mieloide Aguda, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
GLOW, NCT03462719 / 2017-004699-77: A Study of the Combination of Ibrutinib Plus Venetoclax Versus Chlorambucil Plus Obinutuzumab for the First-line Treatment of Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Checkmark New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Dec 2022 - Dec 2022: New data from the P3 GLOW study in combination with ibrutinib in 1L CLL/SLL at ASH 2022
Checkmark Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Dec 2021 - Dec 2021: Data from GLOW trial in combination with Venclexta for CLL at ASH 2021
Checkmark Presentation of data from GLOW trial in combination with Venclexta for CLL/SLL at EHA 2021
More
Active, not recruiting
3
211
Europe, Canada, US, RoW
Ibrutinib, Venetoclax, Chlorambucil, Obinutuzumab, Ibrutinib (as Subsequent Therapy)
Janssen Research & Development, LLC, Pharmacyclics LLC.
Leukemia, Lymphocytic, Chronic, B-Cell
02/21
04/27
NCT02730299 / 2016-000704-28: Stem Cell Transplantation With NiCord® (Omidubicel) vs Standard UCB in Patients With Leukemia, Lymphoma, and MDS

Active, not recruiting
3
125
Europe, US, RoW
NiCord® (omidubicel), Cord Blood Unit
Gamida Cell ltd
Hematological Malignancies, Acute Lymphoblastic Leukemia (ALL), Acute Myelogenous Leukemia (AML), Chronic Myelogenous Leukemia (CML), Myelodysplastic Syndrome (MDS), Lymphoma, Acute Leukemia
04/21
02/25
2020-006048-15: The study aims to verify the greater efficacy of the treatment of Acute Lymphoblastic Leukemia Ph + through the combination of Ponatinib and Blinatumomab, a specific monoclonal antibody, in adult patients, compared to the administration of chemotherapy and Imatinib. Lo studio ha lo scopo di verificare la maggiore efficacia del trattamento della Leucemia Linfoblastica Acuta Ph+ tramite la combinazione di Ponatinib e Blinatumomab, un anticorpo monoclonale specifico, in pazienti adulti, rispetto alla somministrazione di chemioterapia ed Imatinib.

Not yet recruiting
3
236
Europe
Iclusig, Blinatumomab, [NA], Film-coated tablet, Concentrate and solvent for solution for infusion, Iclusig 15 mg compresse rivestite con film, BLINCYTO - 38,5 MICROGRAMMI - POLVERE PER CONCENTRATO E SOLUZIONE PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - POLVERE:FLACONCINO (VETRO) 38,5MCG - SOLUZIONE: 10 ML FLACONCINO (VETRO) - 1 FLACONCINO + 1 FLACONCINO
FONDAZIONE GIMEMA (GRUPPO ITALIANO MALATTIE EMATOLOGICHE DELL' ADULTO) FRANCO MANDELLI ONLUS, Fondazione GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) Franco Mandelli Onlus, Amgen S.r.l. via E. Tazzoli, 6 - 20154 - Milano, Incyte Biosciences International Sàrl, Rue Docteur-Yersin 10, 1110 Morges, Switzerland
Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia. Leucemia acuta linfoblastica Philadelphia-positiva dell'adulto., Acute lymphoblastic leukemia, a blood cancer that begins when the lymphocytes undergo neoplastic transformation in the marrow, with uncontrolled multiplication and progressive accumulation. Leucemia linfoblastica acuta, malattia tumorale del sangue che inizia quando i linfociti subiscono trasformazione neoplastica nel midollo, con moltiplicazione incontrollata e progressivo accumulo., Diseases [C] - Blood and lymphatic diseases [C15]
 
 
SEQUOIA, NCT03336333 / 2017-001551-31: A Study Comparing Zanubrutinib With Bendamustine Plus Rituximab in Participants With Previously Untreated CLL or SLL

Checkmark Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Jul 2021 - Jul 2021: Topline results from SEQUOIA trial in patients with treatment-naïve chronic lymphocytic leukemia
Checkmark Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Dec 2019 - Dec 2019: Presentation of data from SEQUOIA trial in CLL or SLL at ASH 2019
Active, not recruiting
3
590
Europe, US, RoW
Zanubrutinib, BGB-3111, BRUKINSA, Bendamustine, Treanda, Ribomustin, and Levact, Rituximab, Rituxan, MabThera, Venetoclax, Venclexta, Venclyxto
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
05/21
09/26
PANTHER, NCT03268954 / 2017-000318-40: Pevonedistat Plus Azacitidine Versus Single-Agent Azacitidine as First-Line Treatment for Participants With Higher-Risk Myelodysplastic Syndromes (HR MDS), Chronic Myelomonocytic Leukemia (CMML), or Low-Blast Acute Myelogenous Leukemia (AML)

Active, not recruiting
3
454
Europe, Canada, Japan, US, RoW
Azacitidine, Pevonedistat
Takeda, Takeda Development Center Americas, Inc.
Myelodysplastic Syndrome, Leukemia, Myelomonocytic, Chronic, Leukemia, Myeloid, Acute
05/21
09/24
NCT02035462 / 2009-012476-28: CLL11: A Study of RO5072759 (GA101) With Chlorambucil in Patients With Previously Untreated Chronic Lymphocytic Leukemia

Active, not recruiting
3
787
US, Canada, Europe, RoW
RO5072759, rituximab, chlorambucil
Hoffmann-La Roche, F. Hoffmann-La Roche Ltd., , F.Hoffmann-La Roche Ltd.
Lymphocytic Leukemia, Chronic
06/21
06/21
2020-004554-30: A Phase 3 Study Comparing LOXO-305 to Investigator’s Choice of Idelalisib plus Rituximab or Bendamustine plus Rituximab

Ongoing
3
250
Europe, RoW
LOXO-305, Bendamustine Hydrochloride, Rituximab, Idelalisib, [na], Film-coated tablet, Powder for concentrate for solution for infusion, Concentrate for solution for infusion, Bendamustine Accord, Bendamustin cell pharm®, MabThera, Zydelig
Loxo Oncology Inc, LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years., Diseases [C] - Cancer [C04]
 
 
Ascertain, NCT03306264 / 2018-003395-12: Study of ASTX727 vs IV Decitabine in Participants With MDS, CMML, and AML

Checkmark Pharmacokinetic exposure equivalence and preliminary efficacy data from trial for MDS and CMML at ASH 2019
Dec 2019 - Dec 2019: Pharmacokinetic exposure equivalence and preliminary efficacy data from trial for MDS and CMML at ASH 2019
Checkmark Trial initiation in US (untreated high-risk MDS)
Mar 2018 - Mar 2018: Trial initiation in US (untreated high-risk MDS)
Completed
3
227
Europe, Canada, US, RoW
ASTX727, decitabine 35 mg + cedazuridine 100 mg, Dacogen, decitabine
Astex Pharmaceuticals, Inc.
Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, Acute Myeloid Leukemia
09/21
05/23
QuANTUM-First, NCT02668653 / 2015-004856-24: Quizartinib With Standard of Care Chemotherapy and as Continuation Therapy in Patients With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (AML)

Hourglass Apr 2021 - Mar 2022 : Approval in Japan for 1L AML
Hourglass Oct 2021 - Dec 2021 : Top-line data from QuANTUM-First trial for 1L AML
Completed
3
539
Europe, Canada, Japan, US, RoW
Chemotherapy, Cytarabine, Daunorubicin, Idarubicin, Quizartinib, Test Product, Placebo, Placebo Control
Daiichi Sankyo
Acute Myeloid Leukemia, Leukemia
08/21
06/23
2020-004360-26: Comparison of a fixed-duration treatment of acalabrutinib, venetoclax and obinutuzumab to a treatment of venetoclax and obinutuzumab in patients with high risk chronic lymphocytic leukemia Vergleich einer befristeten Therapie mit Acalabrutinib, Venetoclax und Obinutuzumab mit der Therapie von Venetoclax und Obinutuzumab bei Patienten mit chronischer lymphytischer Leukämie mit hohem Risiko

Not yet recruiting
3
178
Europe
Acalabrutinib, Obinutuzumab, Venetoclax, RO5072759, Capsule, hard, Concentrate for solution for infusion, Film-coated tablet, Calquence, Gazyvaro®, Venclyxto
German CLL Study Group (University of Cologne), AstraZeneca
Patients with previously untreated chronic lymphocytic leukemia with treatment requiring disease and at least one out of three risk factors (17p-deletion, TP53 mutation or Complex karyotype)., Patients with chronic lymphocytic leukaemia (blood cancer) in need of firstline treatment and at least one out of three risk factors., Diseases [C] - Cancer [C04]
 
 
2021-000678-27: A study to compare oral asciminib versus existing TKI medicines in patients with newly diagnosed CML Vizsgálat az orálisan alkalmazott asciminib és tirozin-kináz inhibitor (TKI) között újonnan diagnosztizált krónikus mieloid leukémiában (CML) szenvedő betegeknél

Ongoing
3
402
Europe
Asciminib, Bosulif, Glivec, Tasigna, Sprycel, ABL001, STI571, AMN107, Film-coated tablet, Capsule, hard, Bosulif, Glivec, Tasigna, Sprycel
Novartis Pharma AG, Novartis Farmacéutica S.A., Novartis Pharma AG
Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04]
 
 
ASCEND, NCT02970318 / 2015-004454-17: A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL

Checkmark 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Jun 2022 - Jun 2022: 4-year follow up PFS data from ACEND trial for CLL at ASCO 2022
Checkmark From ASCEND trial for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From ASCEND trial for r/r CLL at ASH 2021
Checkmark From ASCEND trial for r/r CLL at EHA 2020
More
Active, not recruiting
3
310
Europe, Canada, US, RoW
Acalabrutinib (ACP-196), Rituximab, Idelalisib, Bendamustine
Acerta Pharma BV
Chronic Lymphocytic Leukemia
09/21
10/27
NCT03406156: A Study in Previously Untreated Chronic Lymphocytic Leukemia (CLL) Subjects, Excluding Those With the 17p Deletion, to Evaluate Debulking Regimens Prior to Initiating Venetoclax Combination Therapy

Completed
3
120
US
Obinutuzumab, Gazyva, Bendamustine, Bendeka, Venetoclax, Venclexta, ABT-199, GDC-0199
AbbVie
Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma (SLL)
10/21
07/23
2021-001234-20: A Phase 3 Study Comparing Pirtobrutinib (LOXO-305) to Bendamustine plus Rituximab in Untreated Patients with CLL/SLL Studio di fase 3 che confronta Pirtobrutinib (LOXO-305) con Bendamustina più Rituximab in pazienti con LLC/SLLnon trattati

Not yet recruiting
3
250
Europe, RoW
Rituximab, Bendamustine Hydrochloride, Pirtobrutinib, [na], [LOXO-305], Concentrate for solution for injection/infusion, Powder for concentrate for solution for infusion, Film-coated tablet, MabThera, Bendamustina Accord, Bendamustin cell pharm®
LOXO ONCOLOGY INCORPORATED, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company, Loxo Oncology Inc, Loxo Oncology Inc., a wholly owned subsidiary of Eli Lilly and Company
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Leucemia linfatica cronica (LLC)/linfoma linfocitico a piccole cellule, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years. La leucemia linfatica cronica (LLC)/il linfoma linfocitico a piccole cellule (SLL) è un tipo di tumore che colpisce i globuli bianchi e tende a progredire lentamente nell’arco di molti anni., Diseases [C] - Cancer [C04]
 
 
2018-001588-22: A phase III clinical study to determine the efficacy and safety of CPI-613 in combination with high dose Cytarabine and Mitoxantrone compared to high dose Cytarabine and Mitoxantrone in adults with a type of cancer called acute myeloid leukemia

Not yet recruiting
3
500
Europe
CPI-613, CPI-613, Solution for injection, Citarabina, Mitoxantrone
Rafael Pharmaceuticals, Inc., Rafael Pharmaceuticals Inc, Rafael Pharmaceuticals, Inc., Rafael Pharmaceuticals, Inc
Acute Myeloid Leukemia, A blood cancer called Acute Myeloid Leukemia, Diseases [C] - Cancer [C04]
 
 
CATHY, NCT04976699: CD24Fc for the Prevention of Acute Graft Versus Host Disease (GVHD) Following Myeloablative Hematopoietic Stem Cell Transplantation (HSCT) (MK-7110-005)

Active, not recruiting
3
11
US
CD24Fc, Human CD24 and human IgG Fc Fusion Protein, Placebo, Saline, Methotrexate, Trexall, Tacrolimus, FK506, Prograf
Merck Sharp & Dohme Corp.
Hematopoietic Stem Cell Transplantation, Acute Graft Versus Host Disease, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes
11/21
11/21
2020-006057-21: Asciminib treatment optimization in ≥ 3rd line CML-CP Optimización del tratamiento con asciminib en LMC-FC en >=3.ª línea

Ongoing
3
186
Europe
Asciminib, ABL001, Film-coated tablet
Novartis Farmacéutica S.A., Novartis Pharma AG, Novartis Pharma AG
Chronic Myelogenous Leukemia in chronic phase (CML-CP) Leucemia mieloide crónica en fasecrónica (LMC-FC), CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells. LMC es un cáncer de médula ósea causado por mutación genética que causa un crecimiento excesivo de los glóbulos blancos., Diseases [C] - Cancer [C04]
 
 
Viale-a, NCT02993523 / 2016-001466-28: A Study of Venetoclax in Combination With Azacitidine Versus Azacitidine in Treatment Naïve Participants With Acute Myeloid Leukemia Who Are Ineligible for Standard Induction Therapy

Checkmark Data from VIALE-A study in combination with azacitidine in 1L AML
Aug 2020 - Aug 2020: Data from VIALE-A study in combination with azacitidine in 1L AML
Checkmark From VIALE-A study in combination with azacitidine for 1L AML
Jun 2020 - Jun 2020: From VIALE-A study in combination with azacitidine for 1L AML
Checkmark Data from VIALE-A trial in combination with azacitidine for 1L unfit AML at EHA 2020
More
Active, not recruiting
3
443
Europe, Canada, Japan, US, RoW
Azacitidine, Venetoclax, ABT-199, Placebo
AbbVie, Genentech, Inc.
Acute Myeloid Leukemia (AML)
12/21
01/26
2019-004375-40: Study for the evaluatiion of Efficacy and Safety of Panzyga in Primary Infection Prophylaxis in Patients with Chronic Lymphocytic Leukemia (“PRO-SID” study) Studie zur Ermittlung der Wirksamkeit und Sicherheit von Panzyga in der primären Infektionsprophylaxe bei Patienten mit chronischer lymphatischer Leukämie ("PRO-SID"-Studie)

Not yet recruiting
3
450
Europe, RoW
Panzyga, [NA], Solution for infusion, Panzyga
Octapharma Pharmazeutika Produktionsges.m.b.H., OCTAPHARMA PHARMAZEUTIKA PRODUKTIONSGES.M.B.H., Octapharma Pharmazeutika Produktionsges.m.b.H.
Primary infection prophylaxis in patients with chronic lymphocytic leukemia (CLL) and secondary hypogammaglobulinemia, Prophylaxis to prevent infection in patients with a type of cancer that starts in bone marrow and then go into the blood, Diseases [C] - Cancer [C04]
 
 
ENDURE-CML-IX, NCT03117816: ENDURE - Efficacy and Safety of AOP2014 With CML Patients in Remission

Completed
3
214
Europe
AOP2014 / Pegylated-Proline-interferon alpha-2b, Surveillance
Philipps University Marburg Medical Center, Deutsche Krebshilfe e.V., Bonn (Germany), AOP Orphan Pharmaceuticals AG
Chronic Myeloid Leukemia in Remission
01/22
12/22
2020-004453-71: Treatment for previously untreated patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) with venetoclax or placebo in combination with chemotherapy. Behandlung von Patienten mit neudiagnostizierter Akuter myeloischer Leukämie (AML) oder Myelodysplastischem Syndrom (MDS) mit Venetoclax oder Placebo in Kombination mit Chemotherapy.

Not yet recruiting
3
650
Europe
Venetoclax, ABT-199, Film-coated tablet,
University Hospital Ulm, University Hospital Ulm, AbbVie Inc.
AML or MDS-EB2 AML oder MDS-EB2, Acute myeloid leukemia or myelodysplastic syndrome Akute myeloische Leukämie oder Myelodysplastisches Syndrom, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2021-003212-11: A study to evaluate if the addition of venetoclax to chemotherapy (fludarabine/cytarabine/gemtuzumab ozogamicin) improves the survival of children with relapsed acute myeloid leukemia. Een onderzoek om te evalueren of de toevoeging van venetoclax aan chemotherapie (fludarabine/cytarabine/gemtuzumab ozogamicine) de overleving verbetert van kinderen met teruggekeerde acute myeloïde leukemie.

Ongoing
3
98
Europe, RoW
Venetoclax for Oral suspension, Abbvie to provide, Tablet, Powder for oral suspension in sachet, Venclyxto
Princess Máxima Center, Princess Máxima Center for Paediatric Oncology, Princess Máxima Center for Oncology, ABBVIE INC., Leukemia & Lymphoma Society (LLS), Princess Máxima Center, Roche/Genentech
Children, adolescents, and young adults up to the age of 21 years with acute myeloid leukemia without FLT3/ITD mutation who are in:- Second relapse, who are sufficiently fit to undergo another round of intensive chemotherapy- First relapse who per investigator discretion cannot tolerate additional anthracycline containing chemotherapy. Kinderen, adolescenten en jongvolwassenen tot en met 21 jaar met acute myeloïde leukemie zonder FLT3/ITD-mutatie die zich in:- Tweede terugval, die voldoende fit zijn om nog een ronde intensieve chemotherapie te ondergaan- Eerste terugval die naar goeddunken van de onderzoeker geen aanvullende antracyclinebevattende chemotherapie kan verdragen., Pediatric patients, adolescentes and adults up to the age of 21 years who suffer from acute myeloid leukemia (a type of blood cancer) who have relapsed (returned after treatment). Pediatrische patiënten, adolescenten en volwassenen tot 21 jaar die lijden aan acute myeloïde leukemie (een vorm van bloedkanker) die is teruggekeerd (teruggekomen na behandeling)., Diseases [C] - Cancer [C04]
 
 
AML21, NCT02172872 / 2014-001486-27: "InDACtion" vs "3+7" Induction in AML

Active, not recruiting
3
606
Europe, RoW
standard combination chemotherapy, "3+7" induction chemotherapy, Intensive combined chemotherapy, decitabine, Dacogen
European Organisation for Research and Treatment of Cancer - EORTC, Janssen Pharmaceuticals, Gruppo Italiano Malattie EMatologiche dell'Adulto
Acute Myeloid Leukemia (AML)
03/22
12/23
SIERRA, NCT02665065: Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia

Checkmark Top line data from SIERRA trial for r/r AML
Oct 2022 - Oct 2022: Top line data from SIERRA trial for r/r AML
Checkmark Data from SIERRA trial for r/r AML
Apr 2022 - Apr 2022: Data from SIERRA trial for r/r AML
Checkmark Patient enrollment completed in P3 SIERRA trial for AML
More
Active, not recruiting
3
153
Canada, US
Iomab-B, Conventional Care, HCT
Actinium Pharmaceuticals
Acute Myeloid Leukemia, Leukemia, Acute Myeloid, Myeloid Leukemia, Acute, Leukemia, Myeloid, Acute, Acute Myelogenous Leukemia, Leukemia, Acute Myelogenous, Myelogenous Leukemia, Acute, AML, Bone Marrow Transplant
06/22
12/26
2021-003206-41: A Phase 3 Study Comparing Pirtobrutinib to Ibrutinib in CLL/SLL

Ongoing
3
650
Europe
Pirtobrutinib, Ibrutinib, LOXO-305, Tablet, Capsule, hard, IMBRUVICA
Loxo Oncology, Inc., Loxo Oncology, Inc.
Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma krónikus limfocitás leukémia / kis limfocitás limfóma, Chronic lymphocytic leukaemia/Small Lymphocytic Lymphoma is a type of cancer that affects the white blood cells and tends to progress slowly over many years, Diseases [C] - Cancer [C04]
 
 
ALPINE, NCT03734016 / 2018-001366-42: A Study of Zanubrutinib (BGB-3111) Versus Ibrutinib in Participants With Relapsed/Refractory Chronic Lymphocytic Leukemia

Checkmark Data from ALPINE trial for CLL at ASH 2022
Dec 2022 - Dec 2022: Data from ALPINE trial for CLL at ASH 2022
Completed
3
652
Europe
Zanubrutinib, BGB-3111, Brukinsa, Ibrutinib, Imbruvica
BeiGene
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/22
02/24
PhALLCON, NCT03589326 / 2018-000397-30: A Study of Ponatinib Versus Imatinib in Adults With Acute Lymphoblastic Leukemia

Checkmark Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Sep 2019 - Sep 2019: Data from PhALLCON Study for newly diagnosed Ph+ ALL at SOHO 2020
Checkmark Initiation of new trial in Ph+ ALL
Jul 2018 - Jul 2018: Initiation of new trial in Ph+ ALL
Active, not recruiting
3
245
Europe, Canada, Japan, US, RoW
Ponatinib, Iclusig, Imatinib, Gleevec, Vincristine, Dexamethasone, Cytarabine, Methotrexate, Prednisone
Takeda
Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL)
08/22
07/27
2019-003913-32: Treatment with Gemtuzumab Ozogamicin in addition to standard induction therapy and comparison of standard postremission therapy versus standard postremission therapy in combination with Glasdegib in patients with newly diagnosed acute myeloid leukemia.

Not yet recruiting
3
252
Europe
Gemtuzumab Ozogamicin, Glasdegib, Powder for concentrate for solution for infusion, Mylotarg
Ruprecht-Karls-University of Heidelberg Medical Faculty represented in law by Heidelberg University Hospital, Heidelberg University Hospital, PFIZER INC.
acute myeloid leukemia (AML), leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
2022-000995-21: A study to compare asciminib versus nilotinib in patients with newly diagnosed CML Egy tanulmány az asciminib és a nilotinib összehasonlítására újonnan diagnosztizált CML-ben szenvedő betegeknél

Ongoing
3
553
Europe, RoW
Asciminib, Tasigna, ABL001, AMN107, Film-coated tablet, Capsule, hard, Tasigna
Novartis Pharma AG, Novartis Pharma AG
Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia in chronic phase (CML-CP) in newly diagnosed patients, CML is a bone marrow cancer caused by a gene mutation which causes over growth of white blood cells., Diseases [C] - Cancer [C04]
 
 
VIALE-M, NCT04102020 / 2019-002217-19: A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Active, not recruiting
3
112
Europe, Canada, Japan, US, RoW
Venetoclax, ABT-199, GDC-0199, Venclexta, Azacitidine
AbbVie, Roche-Genentech
Acute Myeloid Leukemia (AML)
09/22
04/25
NCT03258931: Study of Crenolanib vs Midostaurin Following Induction Chemotherapy and Consolidation Therapy in Newly Diagnosed FLT3 Mutated AML

Recruiting
3
510
US
Crenolanib, Crenolanib besylate, Midostaurin, Cytarabine, Duanorubicin
Arog Pharmaceuticals, Inc.
Newly Diagnosed FLT3 Mutated AML
11/22
11/24
2021-000761-33: Combining chemotherapy with either the medication entospletinib or a placebo for adults with acute myeloid leukemia that has a nucleophosmin-1 abnormality

Not yet recruiting
3
180
Europe, RoW
Entospletinib, ENTO, Film-coated tablet, ARA-cell® 1000 mg solution for infusion50 mg/ml solution for infusion, Idarubicin Hikma 1 mg/mL solution for injection, Daunorubicin 20mg Powder for I.V. Injection
Kronos Bio, Inc., Kronos Bio Inc., Kronos Bio, Inc.
Acute Myeloid Leukemia, Acute Myeloid Leukemia, Diseases [C] - Blood and lymphatic diseases [C15]
 
 
NCT03926624: Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage

Recruiting
3
450
US
DFP-10917, Cytarabine, Azacitidine, Decitabine, Mitoxantrone, Etoposide, Fludarabine, Idarubicin, Venetoclax, Cladribine
Delta-Fly Pharma, Inc.
Leukemia, Myeloid, Acute
12/22
12/22
NCT04571645: Dociparstat in Combination With Standard Chemotherapy for the Treatment of Acute Myeloid Leukemia

Terminated
3
9
US
Dociparstat, DSTAT, CX-01, 2-0,3-0 desulfated heparin, ODSH, dociparstat sodium, Control, 0.9% Normal Saline, Normal saline, Sodium chloride 0.9%
Chimerix
Acute Myeloid Leukemia
05/22
05/22
UNITY-CLL, NCT02612311 / 2015-005758-36: Ublituximab + TGR-1202 Compared to Obinutuzumab + Chlorambucil in Participants With Untreated and Previously Treated Chronic Lymphocytic Leukemia

Checkmark Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Apr 2022 - Apr 2022: Withdrawn sNDA filing in combination with ublituximab for adult patients with CLL and SLL
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Dec 2021 - Dec 2021: From UNITY-CLL trial in combination with ublituximab for r/r CLL at ASH 2021
Checkmark From UNITY-CLL trial in combination with ublituximab for r/r CLL at iwCLL 2021
More
Terminated
3
603
Europe, US, RoW
Obinutuzumab, GAZYVA, Ublituximab, TGR-1202, Chlorambucil, Leukeran
TG Therapeutics, Inc.
Chronic Lymphocytic Leukemia
02/23
02/23
MORPHO, NCT02997202 / 2016-001061-83: A Trial of the FMS-like Tyrosine Kinase 3 (FLT3) Inhibitor Gilteritinib Administered as Maintenance Therapy Following Allogeneic Transplant for Patients With FLT3/Internal Tandem Duplication (ITD) Acute Myeloid Leukemia (AML)

Hourglass Jun 2023 - Jun 2023 : Safety and efficacy data from MORPHO trial in patients with acute myeloid leukemia
Completed
3
356
Europe, Canada, Japan, US, RoW
gilteritinib, Placebo
Astellas Pharma Global Development, Inc., National Heart, Lung, and Blood Institute (NHLBI), Blood and Marrow Transplant Clinical Trials Network
Acute Myeloid Leukemia
01/23
05/23
LACEWING, NCT02752035 / 2015-001790-41: A Study of ASP2215 (Gilteritinib) by Itself, ASP2215 Combined With Azacitidine or Azacitidine by Itself to Treat Adult Patients Who Have Recently Been Diagnosed With Acute Myeloid Leukemia With a FLT3 Gene Mutation and Who Cannot Receive Standard Chemotherapy

Checkmark From trial in combination with azacitidine for FLT3mut+ AML
Dec 2020 - Dec 2020: From trial in combination with azacitidine for FLT3mut+ AML
Active, not recruiting
3
183
Europe, Canada, Japan, US, RoW
gilteritinib, ASP2215, azacitidine
Astellas Pharma Global Development, Inc.
Acute Myeloid Leukemia (AML), Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
03/23
12/24
AGILITY, NCT05020665: Entospletinib Plus Intensive Induction/Consolidation Chemotherapy in Newly Diagnosed NPM1-mutated AML

Terminated
3
15
Europe, Canada, US, RoW
Entospletinib, ENTO, GS-9973, Placebo, Cytarabine, Anthracycline
Kronos Bio
Nucleophosmin 1-mutated Acute Myeloid Leukemia
03/23
03/23
AIM4CML, NCT04666259: Asciminib in Monotherapy for Chronic Myeloid Leukemia in Chronic Phase (CML-CP) With and Without T315I Mutation

Completed
3
56
US
ABL001
Novartis Pharmaceuticals
Chronic Myelogenous Leukemia - Chronic Phase
06/23
06/24
PEVOLAM, NCT04090736: Study to Compare Azacitidine Plus Pevonedistat Versus Azacitidine in Patients With Acute Myeloid Leukemia Not Eligible for Standard Chemotherapy

Hourglass Apr 2023 - Mar 2024 : From PEVOLAM trial in combination with azacitidine for 1L AML
Active, not recruiting
3
302
Europe
Pevonedistat, Azacitidine
PETHEMA Foundation, Millennium Pharmaceuticals, Inc., Dynamic Science S.L.
Leukemia, Myeloid, Acute
06/23
06/23
2012-000793-30: International Study for Treatment of Standard Risk Childhood Relapsed Acute Lymphoblastic Leukemia 2010

Completed
3
1242
Europe, RoW
Epratuzumab, IMMU-103, Solution for infusion, ENDOXAN 200 mg ENDOXAN 500 mg ENDOXAN 1 g, CYTOSAR 100 mg CYTOSAR 500 mg CYTOSAR 1 g, Fortecortin, Etoposid, Zavedos, HOLOXAN, Puri-Nethol, METHOTREXAT, Mitoxantron, Oncaspar, Lanvis, Vincristine, Vindesine, Methotrexate, Methotrexat, CYTOSAR
Charité - University Hospital of Berlin, Manchester University NHS Foundation Trust, Turku University Hospital, EU Project FP7, Deutsche Kinderkrebsstiftung, Immunomedics, Deutsche kinderkrebsstiftung, Turku UNiversity Hospital
Acute lymphoblastic leukemia (ALL), Acute lymphoblastic leukemia (ALL), Diseases [C] - Cancer [C04]
 
 
NCT01724346 / 2012-003968-44: Open-label Extension Study in Patients 65 Years or Older With Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Completed
3
269
Europe, Canada, US, RoW
Ibrutinib, PCI-32765, Next-line ibrutinib
Pharmacyclics LLC., Janssen Research & Development, LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
08/23
NCT05054543: Study to Evaluate the Efficacy of Uproleselan in Combination With Chemotherapy in Chinese Patients With R/R AML

Recruiting
3
140
RoW
Uproleselan, GMI-1271, Placebo, Saline
Apollomics Inc., Zhejiang CrownMab Biotech Co. Ltd
Relapsed/Refractory AML
10/23
02/24
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
ASC4FIRST, NCT04971226 / 2021-000678-27: A Study of Oral Asciminib Versus Other TKIs in Adult Patients With Newly Diagnosed Ph+ CML-CP

Active, not recruiting
3
404
Europe, Canada, Japan, US, RoW
Imatinib, STI571, Nilotinib, AMN107, Bosutinib, Dasatinib, Asciminib, ABL001
Novartis Pharmaceuticals, Novartis Pharma AG
Chronic Myeloid Leukemia (CML) Philadelphia Chromosome Positive
11/23
01/28
BELLWAVE-011, NCT06136559: A Study of Nemtabrutinib (MK-1026) Versus Comparator (Investigator's Choice of Ibrutinib or Acalabrutinib) in First Line (1L) Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL) (MK-1026-011/)

Recruiting
3
1200
Europe, Canada, Japan, US, RoW
Nemtabrutinib, MK-1026, ARQ 531, Ibrutinib, Acalabrutinib
Merck Sharp & Dohme LLC
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
09/32
09/32
NCT04094311: Study of Out of Specification for Tisagenlecleucel

Recruiting
3
200
Canada, Japan
CTL019, Tisagenlecleucel
Novartis Pharmaceuticals
B-cell Acute Lymphoblastic Leukemia, Diffuse Large B-cell Lymphoma
04/25
04/25
NCT03722420: Randomized Evaluation of Radotinib Versus Imatinib in Phase III Study for Efficacy With Chinese Patients (RERISE China)

Active, not recruiting
3
238
RoW
Radotinib, Supect, Imatinib, Glivec
Il-Yang Pharm. Co., Ltd.
Chronic Myeloid Leukemia, Chronic Phase
03/23
06/25
NCT06182592: A Bridging Study of Liposomal Cytarabine-Daunorubicin in Treating Olderly Patients With Treatment-naive High-Risk (Secondary) Acute Myeloid Leukemia

Not yet recruiting
3
120
RoW
Liposomal cytarabine-daunorubicin for injection, 7+3 (cytarabine and daunorubicin)
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd.
High-risk (Secondary) Acute Myeloid Leukemia
02/26
08/26
NCT06205290: A Study to Compare the Efficacy and Safety of Lisocabtagene Maraleucel vs Investigator's Choice Options in Adult Participants With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, Whose Disease Has Failed Treatment With Both BTKi and BCL2i Therapies

Withdrawn
3
200
Europe, US
Liso-cel, JCAR017, Breyanzi®, BMS-986387, lisocabtagene maraleucel, Idelalisib, Zydelig®, Rituximab, Rituxan®, Mabthera®, Riximyo®, Truxima®, Bendamustine, Bendeka®, Treanda®, Belrapzo®, Fludarabine, Fludara®, Bendarabin®, Cyclophosphamide, Endoxan®, Cytoxan®
Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, Celgene Corporation
Leukemia, Lymphocytic, Chronic, B-Cell
10/31
10/31
POLARIS-2, NCT06423911: Study of Olverembatinib (HQP1351) in Patients With CP-CML

Recruiting
3
285
US
olverembatinib, Bosutinib
Ascentage Pharma Group Inc.
Chronic Myeloid Leukemia, CML, CML, Chronic Phase
12/25
02/26
GAIA, NCT02950051 / 2015-004936-36: Standard Chemoimmunotherapy (FCR/BR) Versus Rituximab + Venetoclax (RVe) Versus Obinutuzumab (GA101) + Venetoclax (GVe) Versus Obinutuzumab + Ibrutinib + Venetoclax (GIVe) in Fit Patients With Previously Untreated Chronic Lymphocytic Leukemia (CLL) Without Del(17p) or TP53 Mutation

Hourglass Jan 2021 - Dec 2021 : From CLL13 trial in combination with Venclexta for 1L CLL
Completed
3
926
Europe, RoW
Fludarabine, Fludura, Cyclophosphamide, Endoxan, Rituximab, MabThera, Rituxan, Bendamustine, Ribomustin, Levact, Venetoclax, Venclexta, Venclyxto, Obinutuzumab, Gazyva, Gazyvaro, Ibrutinib, Imbruvica
German CLL Study Group, Janssen-Cilag Ltd., Hoffmann-La Roche, AbbVie, Stichting Hemato-Oncologie voor Volwassenen Nederland, Nordic CLL Study Group (NCLLSG), Swiss Group for Clinical Cancer Research, Cancer Trials Ireland, Israeli CLL Study Group
Chronic Lymphocytic Leukemia
02/24
02/24
COMMODORE, NCT03182244: A Study of ASP2215 Versus Salvage Chemotherapy In Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FLT3 Mutation

Active, not recruiting
3
276
RoW
gilteritinib, ASP2215, LoDAC (Low Dose Cytarabine), MEC (Mitoxantrone, Etoposide, Cytarabine), FLAG (Granulocyte colony-stimulating factor (G-CSF), Fludarabine, Cytarabine)
Astellas Pharma Inc
Acute Myeloid Leukemia With FMS-like Tyrosine Kinase (FLT3) Mutation
12/23
03/26
NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting
3
882
Europe
Cytarabine, Daunorubicin, CPX-351
University of Ulm, Jazz Pharmaceuticals
Acute Myeloid Leukemia
03/24
03/24
ENHANCE-2, NCT04778397 / 2020-003949-11: Study of Magrolimab in Combination With Azacitidine Versus Physician's Choice of Venetoclax in Combination With Azacitidine or Intensive Chemotherapy in Patients With TP53 Mutant Acute Myeloid Leukemia That Have Not Been Treated

Calendar Jan 2023 - Dec 2024: Submission in combination with azacitidine in patients with TP53 mutant AML (based on ENHANCE-2 trial)
Calendar Jul 2024 - Dec 2024: Data from P3 ENHANCE-3 trial in combination with azacitidine for 1L unfit AML
Calendar Jul 2024 - Dec 2024: Data from ENHANCE-2 trial in combination with azacitidine in patients with TP53 mutant AML
Checkmark Pooled analysis data from ENHANCE-1 and ENHANCE-2 trials for COPD
Dec 2022 - Dec 2022: Pooled analysis data from ENHANCE-1 and ENHANCE-2 trials for COPD
More
Terminated
3
258
Europe, Canada, Japan, US, RoW
Magrolimab, GS-4721, Venetoclax, Azacitidine, Cytarabine, Daunorubicin, Idarubicin, Steroidal Eye Drops
Gilead Sciences
Acute Myeloid Leukemia
03/24
03/24
 

Download Options